Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Accuray Inc

NASDAQ: ARAY · Industrial Applications and Services · 6 alerts · CIK 1138723

Share price
$2.55Close, Nov 16
Market cap
$306M
Shares outstanding
120.16MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Accuray Inc filings on SEC EDGAR ↗

4:05 PM ET 10-Q
Financial Results

Accuray Q1 2026 Results: Turns Profitable, Net Income $10.1M

Accuray reported a net income of $10.1 million for the quarter ended September 30, 2026, compared to a net loss of $21.7 million in the prior year, primarily driven by a $59.6 million gain on debt extinguishment. Total net revenue decreased to $86.5 million from $93.9 million, and the company recorded a significant $35.4 million goodwill impairment charge during the period.

Key figure
Net income $10.1M
4:05 PM ET 8-K
Financial Results

Accuray Financial Results

Accuray reported fiscal 2027 first quarter results with total net revenue of $86.5 million, an 8% decrease year-over-year, primarily due to lower product revenue. The company recorded a $35.4 million non-cash goodwill impairment charge but noted that transformation initiatives generated $13 million in cost and margin improvements.

“As I said on our last call, fiscal 2026 was a year of transformation, and fiscal 2027 is about execution. During the first quarter, we made progress across several areas. Service margins improved, operating expenses remained well controlled, we strengthened our financial position, and we advanced our innovation roadmap through strategic partnerships with RaySearch and Samsung NeuroLogica.”

Steve La Neve, President and Chief Executive Officer

“At the same time, we see a clear opportunity to improve product and order performance. The customer engagement we saw at ASTRO, the growing clinical evidence supporting precision radiation therapy, and the opportunities created by our innovation strategy reinforce our confidence in the direction we are taking.”

Steve La Neve, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.